Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma
Anshuman Panda, … , Gyan Bhanot, W. Kimryn Rathmell
Anshuman Panda, … , Gyan Bhanot, W. Kimryn Rathmell
Published August 23, 2018
Citation Information: JCI Insight. 2018;3(16):e121522. https://doi.org/10.1172/jci.insight.121522.
View: Text | PDF
Research Article Immunology Oncology

Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma

  • Text
  • PDF
Abstract

Although a subset of clear cell renal cell carcinoma (ccRCC) patients respond to immune checkpoint blockade (ICB), predictors of response remain uncertain. We investigated whether abnormal expression of endogenous retroviruses (ERVs) in tumors is associated with local immune checkpoint activation (ICA) and response to ICB. Twenty potentially immunogenic ERVs (πERVs) were identified in ccRCC in The Cancer Genome Atlas data set, and tumors were stratified into 3 groups based on their expression levels. πERV-high ccRCC tumors showed increased immune infiltration, checkpoint pathway upregulation, and higher CD8+ T cell fraction in infiltrating leukocytes compared with πERV-low ccRCC tumors. Similar results were observed in ER+/HER2− breast, colon, and head and neck squamous cell cancers. ERV expression correlated with expression of genes associated with histone methylation and chromatin regulation, and πERV-high ccRCC was enriched in BAP1 mutant tumors. ERV3-2 expression correlated with ICA in 11 solid cancers, including the 4 named above. In a small retrospective cohort of 24 metastatic ccRCC patients treated with single-agent PD-1/PD-L1 blockade, ERV3-2 expression in tumors was significantly higher in responders compared with nonresponders. Thus, abnormal expression of πERVs is associated with ICA in several solid cancers, including ccRCC, and ERV3-2 expression is associated with response to ICB in ccRCC.

Authors

Anshuman Panda, Aguirre A. de Cubas, Mark Stein, Gregory Riedlinger, Joshua Kra, Tina Mayer, Christof C. Smith, Benjamin G. Vincent, Jonathan S. Serody, Kathryn E. Beckermann, Shridar Ganesan, Gyan Bhanot, W. Kimryn Rathmell

×

Figure 3

RNA expression of ERV3-2 predicts the response to immune checkpoint blockade in ccRCC.

Options: View larger image (or click on image) Download as PowerPoint
RNA expression of ERV3-2 predicts the response to immune checkpoint bloc...
(A) Expression of ERV3-2 is significantly higher in tumors from responders compared with tumors from nonresponders and is an excellent predictor of response to immune checkpoint blockade for both primers. Green arrows mark the optimal cutoffs that were subsequently used to stratify patients into ERV3-2+ or ERV3-2− groups for consistency checks. (B) The ERV3-2+ group has significantly higher objective response rates and longer progression-free survival compared with the ERV3-2− group for both primers. (C) In contrast, πERV-high/intermediate subtypes have shorter overall survival under standard therapy compared with πERV-low subtype in TCGA ccRCC (KIRC) cohort. The number of samples is specified in each panel. P values reported in bar plots, box plots, and Kaplan-Meier plots are from Fisher’s exact test, Wilcoxon rank-sum test, and log-rank tests, respectively (all 2 sided).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts